Isotechnika Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not ... Equities.com "Our emphasis on nephrology remains intact and we continue to have full confidence in the potential of voclosporin to address significant unmet medical needs like kidney transplant rejection and lupus nephritis." About Isotechnika Pharma Inc ... |
